Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl-dependent mechanisms

WENBIN XU1, WEI WEI2, QING YU1, CHAO WU1, CHENJING YE1, YINGLI WU2 and HUA YAN1,3

1Exclusive Medical Care Center, Rui-Jin Hospital; 2Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education; 3Department of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai 200025, P.R. China

Received October 12, 2013; Accepted April 28, 2014

DOI: 10.3892/mmr.2014.2333

Abstract. Arsenic trioxide (As2O3) and the proteasome inhibitor bortezomib (BTZ) have been used successfully to treat acute promyelocytic leukemia and multiple myeloma. Their synergistic effects with other anticancer drugs have been widely studied. In this study, interactions between As2O3 and BTZ were examined in imatinib-resistant Bcr/Abl+ (K562r) cells. Co-treatment of K562r cells with subtoxic concentrations of As2O3 (2 μM) and BTZ (24 nM) resulted in a synergistic enhancement in growth inhibition and apoptosis, as demonstrated by increased annexin V staining. These events were associated with activation of protein kinase Cδ, poly ADP-ribose polymerase cleavage and caspase-3 activation, along with downregulation of Bcr/Abl mRNA and Bcr/Abl protein expression levels during apoptosis. In addition, reactive oxygen species were downregulated during combined treatment in K562r cells. Collectively, these findings suggest that BTZ and As2O3 act synergistically to induce apoptosis in K562r cells. Therefore, further studies are required to assess the potential of BTZ and As2O3 combinatory treatment of chronic myeloid leukemia, particularly using imatinib-resistant Bcr/Abl+ clones.

Introduction

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder of the bone marrow stem cells characterized by genetic translocation between chromosomes 9 and 22. This translocation results in the fusion of Bcr on chromosome 9, leading to the expression of the Bcr/Abl fusion oncoprotein. This fusion protein exhibits constitutively active kinase activity (1), transducing signals to a variety of downstream survival pathways, including the mitogen-activated protein kinase/extracellular signal-regulated kinase cascade, Akt, and the signal transducers and activators of transcription (STATs) and nuclear factor κB (NF-κB) pathways (2-4). A number of anti-apoptotic proteins, such as B-cell lymphoma extra large, are upregulated as a result of the activation of these pathways. Collectively, these events provide Bcr/Abl+ cells with a survival advantage over normal cells, due to their reduced capacity to undergo apoptosis. Furthermore, Bcr/Abl+ cells have exhibited varying degrees of resistance towards conventional cytotoxic drugs (5-7), until the recent clinical application of imatinib mesylate (Gleevec®, STI-571). Imatinib has been widely demonstrated to be effective in the treatment of CML through inhibition of the tyrosine kinase activity of Bcr/Abl. However, acquired resistance to imatinib can occur through various mechanisms, thereby leading to continued disease progression. Thus, the development of alternative approaches to the treatment of CML is required.

Bortezomib (BTZ), also known as Velcade® or PS-341, has been shown to act as an inducer of apoptosis in multiple myeloma cells. BTZ exerts its effects through a number of signaling cascades, predominantly the NF-κB pathway, ultimately inducing apoptosis and thereby reversing drug resistance and improving prognosis (8,9). The administration of BTZ as a combination treatment with other agents has been widely investigated; the cyclin-dependent kinase inhibitor flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid have both been shown to act synergistically with BTZ to induce apoptosis in Bcr/Abl+ cells (10,11).

Arsenic trioxide (As2O3) is a chemotherapeutic agent that acts by inducing apoptosis and differentiation and can uniquely induce complete remission in the majority of patients with acute promyelocytic leukemia (12-14). Furthermore, studies have shown that As2O3 alone, and in combination with other compounds, induces apoptosis and/or growth arrest in Bcr/Abl+ cells (15-17). However, high concentrations of As2O3 on chromosome 9, leading to the expression of the Bcr/Abl fusion oncoprotein. This fusion protein exhibits constitutively active kinase activity (1), transducing signals to a variety of downstream survival pathways, including the mitogen-activated protein kinase/extracellular signal-regulated kinase cascade, Akt, and the signal transducers and activators of transcription (STATs) and nuclear factor κB (NF-κB) pathways (2-4). A number of anti-apoptotic proteins, such as B-cell lymphoma extra large, are upregulated as a result of the activation of these pathways. Collectively, these events provide Bcr/Abl+ cells with a survival advantage over normal cells, due to their reduced capacity to undergo apoptosis. Furthermore, Bcr/Abl+ cells have exhibited varying degrees of resistance towards conventional cytotoxic drugs (5-7), until the recent clinical application of imatinib mesylate (Gleevec®, STI-571). Imatinib has been widely demonstrated to be effective in the treatment of CML through inhibition of the tyrosine kinase activity of Bcr/Abl. However, acquired resistance to imatinib can occur through various mechanisms, thereby leading to continued disease progression. Thus, the development of alternative approaches to the treatment of CML is required.

Bortezomib (BTZ), also known as Velcade® or PS-341, has been shown to act as an inducer of apoptosis in multiple myeloma cells. BTZ exerts its effects through a number of signaling cascades, predominantly the NF-κB pathway, ultimately inducing apoptosis and thereby reversing drug resistance and improving prognosis (8,9). The administration of BTZ as a combination treatment with other agents has been widely investigated; the cyclin-dependent kinase inhibitor flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid have both been shown to act synergistically with BTZ to induce apoptosis in Bcr/Abl+ cells (10,11).

Arsenic trioxide (As2O3) is a chemotherapeutic agent that acts by inducing apoptosis and differentiation and can uniquely induce complete remission in the majority of patients with acute promyelocytic leukemia (12-14). Furthermore, studies have shown that As2O3 alone, and in combination with other compounds, induces apoptosis and/or growth arrest in Bcr/Abl+ cells (15-17). However, high concentrations of As2O3

Correspondence to: Dr Hua Yan, Department of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, 197 Ruijin Er Road, Shanghai 200025, P.R China E-mail: yanhua_candy@163.com

Key words: arsenic trioxide, bortezomib, chronic myelogenous leukemia, resistant, apoptosis
were used in these studies, and, due to the toxic nature of arsenic, its use has been limited in clinical practice. In 2007, Yan et al. (18) showed that clinically achievable concentrations of As$_2$O$_3$ could act synergistically with BTZ to successfully induce apoptosis in imatinib-sensitive Bcr/Abl+ (K562) cells, in which protein kinase Cb (PKCb) activation played a critical role.

This study aimed to investigate the effects of the combination of As$_2$O$_3$ and BTZ on apoptosis in imatinib-resistant Bcr/Abl+ cells and to determine whether this combinatory approach warranted further investigation as a potential therapeutic strategy for the treatment of CML, particularly for cases exhibiting imatinib resistance.

Materials and methods

Reagents. Imatinib (STI571) was purchased from Selleck Chemicals (Houston, TX, USA), prepared as a 1 mM stock solution in dimethyl sulfoxide and stored at -20°C. BTZ (Millennium Pharmaceuticals Inc., Cambridge, MA, USA) was dissolved in phosphate-buffered saline (PBS) and stored at -20°C until use. As$_2$O$_3$ (Sigma, St. Louis, MO, USA) was dissolved in 1.0 N NaOH and then diluted to 1 mM with PBS.

Cell culture and viability assay. K562 and K562r cells (provided by Professor JV. Melo, Department of Haematology, Imperial College of London, London, UK) were cultured in RPMI-1640 media supplemented with 10% heat-inactivated fetal bovine serum (Gibco-BRL, Gaithersburg, MD, USA) in a humidified atmosphere with 5% CO$_2$ at 37°C. K562r cells were cultured in 1 µM imatinib to maintain drug-resistance. Cells viability and inhibition of cell growth were estimated using a Cell Counting kit 8 (Dojindo Laboratories, Kumamoto, Japan).

Apoptosis assessment. Apoptosis was measured using a fluorescein isothiocyanate (FITC) Annexin V Apoptosis Detection kit (BD Biosciences, Franklin Lakes, NJ, USA) in accordance with the manufacturer's instructions. Following treatment with As$_2$O$_3$ and/or BTZ, 1×10$^5$ K562r cells were collected, washed with cold PBS and resuspended with binding buffer. A total of 5 µl annexin V-FITC was added and cells were incubated for 5 min in the dark. Following incubation, 10 µl propidium iodide was added and the samples were incubated for an additional 3 min. Binding buffer (400 µl) was then added and cells were analyzed by flow cytometry.

Western blot analysis. Equal amounts of protein were loaded on 8-14% SDS-polyacrylamide gels, subjected to SDS-PAGE and transferred to nitrocellulose membranes (Amersham Pharmacia Biotech, Amersham, UK). The blots were stained with 0.2% Ponceau S red to ensure equal protein loading. Following blocking with 5% nonfat milk in PBS, the membranes were probed with primary antibodies targeting c-Abl, PKCd, poly (ADP-ribose) polymerase (PARP) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and cleaved caspase-3 (Cell Signaling Technology, Inc., Beverly, MA, USA). Membranes were subsequently incubated with horse-radish peroxidase (HRP)-linked secondary antibodies (Cell Signaling Technology, Inc.) and the signal was detected using a chemiluminescence Phototope®-HRP kit (Cell Signaling Technology, Inc.). Blots were stripped and reprobed with a mouse anti-β-actin monoclonal antibody (Oncogene, San Diego, CA, USA) as a loading control.

Quantitative polymerase chain reaction (qPCR) analysis of Bcr/Abl mRNA. Total RNA was isolated by TRIZol™ reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) and RNA was treated with DNase (Promega Corp., Madison, WI, USA). Complementary DNA was synthesized according to the manufacturer's instructions. The analysis of Bcr/Abl and β-actin was performed by qPCR using SYBR Green PCR Master Mix reagents (Applied Biosystems, Foster City, CA, USA) using an ABI PRISM 7900 system (Applied Biosystems). The specific primers used for detecting p210 Bcr/Abl were as follows: Forward primer (5'-CTGGCCCAACGATGCGCA-3') and reverse primer (5'-CACTCAGACCTGAGGCTCAA-3'). Primers were synthesized by Sangon Biotechnology (Shanghai, China).

Measurement of reactive oxygen species (ROS). Cells were incubated with either As$_2$O$_3$, BTZ or the two in combination for the indicated times. Following incubation, cells were washed twice with PBS and treated with 10 µM 2',7'-dichlorodihydrofluorescein diacetate (Molecular Probes®/Invitrogen Life Technologies) for 30 min at 37°C, in the dark. Cells were then washed with PBS once. Red fluorescence was detected by fluorescence-activated cell sorting at an excitation wavelength of 485 nm and an emission wavelength of 535 nm.

Statistical analysis. All experiments were repeated in triplicate. The SPSS 11.0 (SPSS Inc., Chicago, IL, USA) software package was used for statistical analysis. P<0.05 was considered to indicate a statistically significant difference. Results are presented as the mean ± standard deviation.

Results

K562r cells are more resistant than K562 cells to imatinib treatment. In order to determine the resistance characteristics of K562r cells, K562 (imatinib-sensitive) or K562r (imatinib-resistant) cells were incubated with varying concentrations of imatinib. Of note, 0.5 µM imatinib caused the downregulation of Bcr/Abl protein expression in K562 cells, whereas 10 µM imatinib was required to inhibit 50% cell growth in K562r cells (Fig. 1A and B). Western blot analysis showed that 1 µM imatinib caused the downregulation of Bcr/Abl protein expression in K562 cells, whereas 25 µM imatinib was required to observe measurable downregulation in K562r cells (Fig. 1C and D).

BTZ synergistically interacts with As$_2$O$_3$ to induce apoptosis in K562r cells. Treatment with either BTZ or As$_2$O$_3$ alone inhibited cell growth in K562r cells in a dose- and time-dependent manner (Fig. 2A and B). To evaluate the potential synergistic effects of these two agents, BTZ and As$_2$O$_3$ were used at concentrations of 24 nM and 2 µM, respectively, the individual half maximal concentration (IC$_{50}$) of these agents in the inhibition of K562r cell growth. Neither of these concentrations elicited significant apoptosis-inducing effects. After 24-48 h of combined incubation with BTZ and As$_2$O$_3$, growth inhibition and apoptosis induction were significantly enhanced in K562r...
cells as compared with those administered a single treatment (P<0.05) (Fig. 2C and D).

**Combined treatment with BTZ and As$_2$O$_3$ results in enhanced caspase-3 activation and PARP and PKCδ cleavage.** Western blot analysis was performed to assess apoptosis-associated events during combined treatment with BTZ and As$_2$O$_3$ in K562r cells. Treatment with 24 nM BTZ or 2 µM As$_2$O$_3$ alone resulted in only minimal effects, whereas combined treatment with BTZ and As$_2$O$_3$ for up to 48 h resulted in a significant increase in caspases-3 activation, as well as enhanced PARP and PKCδ cleavage (Fig. 3).

**Combined treatment with BTZ and As$_2$O$_3$ downregulates Bcr/Abl mRNA and protein expression.** The Bcr/Abl kinase can inhibit apoptosis through multiple mechanisms, leading Bcr/Abl$^+$ cells to develop resistance to apoptosis induced by conventional agents (5-7). In the present study, the effects of 24 nM BTZ and/or 2 µM As$_2$O$_3$ on Bcr/Abl mRNA and protein expression were examined. The results showed that single treatment with either BTZ or As$_2$O$_3$ alone could decrease Bcr/Abl mRNA and protein expression to a moderate extent; however, combined treatment with the two agents resulted in a significant decrease in Bcr/Abl expression in K562r cells (P<0.01), most markedly after 48 h of incubation (Fig. 4A and B). This effect was further confirmed by the Bcr/Abl protein downregulation analyzed by western blotting.

**BTZ enhances As$_2$O$_3$-induced downregulation of ROS in K562r cells.** As$_2$O$_3$ has been reported to exert
pro- or anti-apoptotic effects via manipulating cellular oxidative stress, whilst BTZ is considered to be an inducer of ROS (19-21). The effects of As$_2$O$_3$ and/or BTZ on ROS production in K562r cells were next investigated. The results showed that treatment with As$_2$O$_3$ alone exhibited a marginal decrease in ROS production, whilst that with BTZ elicited an increase in ROS levels. Of note, although As$_2$O$_3$ and BTZ exerted opposing effects, combined treatment with both agents significantly downregulated ROS production. Parallel experiments were performed in K562 cells and comparable results were produced (Fig. 5A and B).

**Discussion**

Despite the success of imatinib, the emergence of drug resistance and disease progression in CML remains a continuing problem (22). In the present *in vitro* study, it was found that the IC$_{50}$ of imatinib in K562r cells was up to 20-fold greater than that in K562 cells and clinically unachievable concentrations of up to 20 μM were required to downregulate Bcr/Abl protein. Thus, the identification of alternative drugs or targets is of great importance. It has been suggested that, instead of inhibiting the tyrosine kinase activity, targeting the signaling pathways downstream of Bcr/Abl or downregulating Bcr/Abl expression could be an effective strategy to overcome imatinib resistance (23). Following the success of BTZ in the treatment of myeloma, proteasome inhibitors have gained interest as novel treatment strategies for cancer. As summarized by a number of studies (10,11,18,24), proteasome inhibitors, including BTZ, may exhibit anti-leukemic activities when used alone and may increase the sensitivity of cancer cells to various anti-cancer agents, including flavopiridol, histone deacetylase inhibitors and As$_2$O$_3$. The combination treatment of As$_2$O$_3$ and BTZ has been widely reported to induce apoptosis in numerous leukemia cell lines (18,25-27). Among these studies, a report by Yan *et al* (18) showed that As$_2$O$_3$ and BTZ interacted synergistically to enhance apoptosis in imatinib-sensitive K562 cells, predominantly through PKCδ activation and decreased NF-κB activity. In the present study, the data showed that clinically
achievable concentrations of BTZ and As$_3$O$_3$ could synergistically inhibit cell growth and induce apoptosis in K562r cells that were resistant to imatinib treatment. Thus, these data support the potential use of this combinatory therapy in the treatment of imatinib-resistant leukemia.

The caspase cascade is a protease system that directly facilitates apoptosis. Activation of caspase-3, the endpoint of this cascade, is critical in cleaving numerous substrates, including the repair enzyme PARP, leading to DNA strand breaks and eventually apoptosis. Caspase-3-mediated cleavage of PARP has been shown to induce apoptosis in various malignant cell lines, including Caco-2 colon cancer cells (28). Consistent with previous reports, the present study also identified that the serial activity of caspasases was involved in inducing apoptosis in combined treatment with BTZ and As$_3$O$_3$ in CML cells, further supporting the use of this treatment in chemotherapies for CML (18,26-27).

The Bcr/Abl kinase plays a key role in the pathogenesis of Bcr/Ab1+ malignancies by blocking apoptosis through multiple pathways, including NF-κB, Akt and STAT signaling cascades (29). As reported both in vitro and in vivo, the overexpression of Bcr/Abl kinase represents a major mechanism of resistance to imatinib (22,30). Wei et al (31) reported that allantolactone could significantly induce apoptosis in K562r cells and that this mechanism involved the knockdown of Bcr/Abl protein expression, resulting in increased apoptosis. Thus, 24 nM BTZ and 2 μM As$_3$O$_3$ were tested in combination in K562r cells and the expression levels of Bcr/Abl were analyzed. Of note, while each agent alone minimally affected the expression of Bcr/Abl, combined treatment led to a marked downregulation of Bcr/Abl mRNA and protein, thus providing important insights into the mechanisms through which these drugs exert their effects.

ROS act as important regulators of apoptosis through numerous signaling pathways (19). A previous study reported that As$_3$O$_3$ and BTZ alone or in combination with other agents could induce ROS production and subsequent apoptosis in several cell lines, including NB4 cells (20). However, certain studies have shown contradictory results, such as a study by Stepnik et al (21), which showed that 5 μM As$_3$O$_3$ induced >20-fold increase in the generation of ROS in HL-60 cells after 6 h of exposure, whereas a 35% decrease was noted in K562 cells under the same conditions. This indicated that the ROS response in cells was strongly dependent on the cell origin, concentration of drugs, time of exposure and other parameters (21). Additionally, the Bcr/Abl kinase is known to enhance ROS production in certain Bcr/Abl-expressing hematopoietic cells and imatinib could effectively reduce ROS production during apoptosis (32-34). In the present study, the effects of the BTZ/As$_3$O$_3$ combination on ROS production at 6, 12 and 24 h of incubation were investigated. Of note, 2 μM As$_3$O$_3$ moderately decreased ROS levels, while 20 nM BTZ had only a minor promoting effect on ROS levels; however, the combined treatment markedly downregulated ROS production in a time-dependent manner. These data showed that BTZ/As$_3$O$_3$ treatment could directly reduce ROS production in K562r cells and that Bcr/Abl downregulation further enhanced this effect.

Collectively, this study showed that BTZ and As$_3$O$_3$ synergistically induced apoptosis in Bcr/Ab1+ K562r cells via caspase-3 activation and downregulation of Bcr/Abl kinase; reduced ROS production appeared to be involved in the underlying mechanism. These findings indicate that combined treatment of BTZ and As$_3$O$_3$ may be a potential therapeutic regimen for the treatment of imatinib-resistant CML.

Acknowledgements

This study was supported in part by the National Natural Science Foundation (grant nos. 81170509 and 30700334). The authors would like to thank Professor J.V. Melo for kindly providing the K562 and K562r cells.

References


